Drug discovery and development is a complex and challenging process that requires the identification and characterization of novel drug targets. Proteomics, the large-scale analysis of proteins, is an increasingly important tool in this effort, providing a powerful means to understand disease mechanisms, discover biomarkers, and profile drug pharmacology. Mass spectrometry, a key technology in proteomics, offers high resolution, reproducible and actionable data on a wide range of protein targets.

In this webinar, Jeffrey Silva, PhD, a Principal Scientist in the Proteomics Group at Cell Signaling Technology will provide an overview of how mass spectrometry-based proteomics can be used for drug discovery and development. Jeffrey will also present several case studies highlighting how these techniques can be used to gain a deeper understanding of disease mechanisms and as a powerful tool for drug discovery.

Key learning objectives include:
  • Understand the role of proteomics and mass spectrometry in drug discovery and development

  • How to use these techniques to probe disease drivers and drug pharmacology

  • How proteomics can be used to discover protein or post-translational modification (PTM) biomarkers

  • How to monitor low abundance proteins or critical PTMs using mass spectrometry

Who should attend?
  • Searching for diagnostic proteomic biomarkers to monitor drug efficacy or disease progression

  • Trying to identify on- & off-target effects of small molecule inhibitors or PROTAC-mediated degradation

  • Identifying critical signaling pathways modulated upon compound treatment or onset of disease
Jeffrey C. Silva, PhD
Principal Scientist, Proteomics at Cell Signaling Technology
Dr. Jeffrey Silva received his undergraduate bachelor’s degree at Merrimack College in North Andover, Massachusetts, with a major in chemistry and minor in biochemistry. He pursued his PhD at Johns Hopkins University, where he studied aflatoxin biosynthesis in Aspergillus, utilizing molecular biology techniques to isolate the gene cluster for the biosynthetic machinery of the polyketide natural product and express a key enzyme (versicolorin B synthase) for active site mechanistic studies. He attended a postdoctoral fellowship at Harvard Medical School where he studied bacterial two-component signal transduction of vancomycin-resistant Enterococci (vanRS) in an E.coli model system. His interest in natural product biosynthesis and signal transduction led him to join a start-up Biotech company called Microbia in 1998, which engineered microbial organisms by altering endogenous signal transduction to program overproduction of pharmaceutically relevant natural products (ie. penicillin & lovastatin). In 2001, he joined Waters Corporation to immerse himself in mass spectrometry and Proteomics and helped develop a novel application called DIA (data independent acquisition) for global protein analysis using liquid chromatography and high-resolution mass spectrometry (DIA-LC-MS). In 2005, he joined Cell Signaling Technology to lead a Proteomics service group that utilized unique immuno-affinity capture reagents with LC-MS at tools to probe cellular signaling and protein post-translational modifications for drug discovery and disease biology. In 2015, he joined a start-up company called Adeptrix Corporation, and served as their Chief Technology Officer to develop a microarray technology platform that utilized single-bead immunoaffinity capture with MALDI mass spectrometry as an efficient method for targeted proteomics, with products and applications in virology, neurology, oncology and food-OMICs. Dr. Silva recently returned to Cell Signaling Technology in 2023 as a Principal Scientist in the Proteomics group, where he continues to champion the integration of immunoaffinity reagents with the mass spectrometry as powerful tools for translational research.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Organization / Company*
Job Title*
Country / Region*
Main Application Area(s)*
Cell Biology
Developmental Biology / Stem Cells
Infectious Disease
Genetics / Genomics
Have a question for Jeffrey? Ask it here:
Registration Terms
This event is hosted by the Scientist.com family of companies. Specific brands and sites associated with this event include InsideScientific. By registering and participating, you acknowledge that your personal data will be processed by the webinar platform (BigMarker) and Scientist.com. You also agree to receive email communication from Scientist.com and InsideScientific about this webinar and other programs of similar nature. The sponsor of this webinar is Cell Signaling Technology (CST); by registering and participating, you acknowledge that your data will be processed in accordance with CST's Privacy Policy. You will receive email communication from CST about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Yes, I consent to the registration terms.*
Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.